Resumen

SERRANO, JC; BALL, M; VELASQUEZ, D  y  GONZALEZ, M. Papel de los Calcio-Antagonistas en el control de eventos Vaso-Oclusivos y Hemolíticos en Drepanocitosis. Estudio piloto con Nitrendipina. AVFT [online]. 2001, vol.20, n.2, pp.152-162. ISSN 0798-0264.

Antecedents: Recently began the study on drugs able to inhibit the loss of water and K+, dependent of calcium from the red cell, by means of the blockade of Gardo´s Channel, as a therapeutic measure to avoid the sickling phenomenon. Our study tries to establish the rol of the nitrendipin in the control of the clinical and paraclinical manifestations in sickle cell disease. Methods: We carried out a randomized, placebo controlled clinical trial, on single blind fashion with groups in parallel, two dose levels, of 10 weeks of duration. Twenty six patients were included (16 women and 10 men) distributed at rabdom in three groups to receive placebo or nitrendipin to 20 mg/day or nitrendipin to 30 mg/day. Results: In both treatment groups with nitrendipin, a tendency was appreciated toward a lower frequency of occlusives events with a smaller proportion of affected patients, but without achieving a statistically significant difference in the mean of events per patient or in mean intensity of pain in each group. The nitrendipin achieved a significant reduction in the reticulocite percentage and in the basal levels of indirect bilirrubina at both dose levels with regard to the placebo group (intergroup and intragroup comparison: p <0.05). The rest of the parameters didn’t modify. The drug was safe and well tolerated. Conclusions: The nitrendipin reduced some haemolitic markers (% of reticulocites and indirec bilirrubin). The true therapeutic potential of tris drug should be confirmed in new controlled trials.

Palabras clave : Nitrendipin; Sickle cell disease; Controlled study; Gardos channel; Intraglobular Potassium.